CHDArrhythmiasDiabetesLipidologyHeart FailureHypertensionStrokeThrombosis
Log in
Username
Password
Remember me
Bookmark this site|Register Me|Forgotten Password
Welcome to InCirculation.net
InCirculation.net is a professional cardiovascular resource intended for a global audience of specialists, generalists, researchers, and other healthcare professionals
Would you like to know what else InCirculation.net has to offer? Take the tour of InCirculation.net
Click here to register

Cardiovascular News



Page summary
Text size
News quick search
Cardiovascular news provides daily news updates to help you stay informed.
 

Hemoglobin glycation reflects lipid levels


7 September 2007

MedWire News: Levels of glycated hemoglobin (HbA1c) offer a good indication of the lipid profile of patients with Type 2 diabetes, study results suggest.

"There were no significant interactions between sex or age and HbA1c with respect to lipid profile, suggesting the validity of HbA1c for predicting dyslipidemia irrespective of patients' gender and age," says Haseeb Ahmad Khan, from King Saud University in Riyadh, Saudi Arabia.

Writing in the journal Acta Diabetologia, Khan reports the findings from a study of 2220 patients with Type 2 diabetes. The patients were aged between 35 and 91 years and 1072 were women.

Overall, 13.5% of the patients had good glycemic control (HbA1c <7%), 51.8% had moderate glycemic control (HbA1c 7-9%), and 34.7% had poor glycemic control (HbA1c >9%).

Dyslipidemia worsened with deteriorating glycemic control, most notably for triglyceride levels, which rose from 1.66 mmol/l (145.6 mg/dl) to 1.88 mmol/l (164.9 mg/dl) and then 2.13 mmol/l (186.8 mg/dl) in patients with good, moderate, and poor glycemic control, respectively.

The percentage of HbA1c correlated significantly and positively with levels of total cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides, with these explaining 11.5%, 8.3%, and 16.6% of the variation in HbA1c, respectively.

The percentage of HbA1c also correlated negatively with high-density lipoprotein (HDL) cholesterol level, with the latter explaining 7.4% of the variation in the former.

"Early therapeutic interventions, aiming to reduce triglycerides and LDL and to increase HDL, significantly reduce cardiovascular events and mortality in patients with Type 2 diabetes," says Khan.

He observes that the "dual biomarker capacity of HbA1c (glycemic control as well as lipid profile indicator) may be utilized for screening high-risk diabetic patients for timely intervention with lipid-lowering drugs."

Acta Diabetol 2007; Advance online publication



© Copyright Current Medicine Group, 2010

Related Content

All rights reserved. This website is intended for an international audience. Privacy PolicyLegal NoticeTerms and Conditions